Why the study?
Ewing sarcoma patients often develop drug resistance leading to progression, but unique tumorigenesis characteristics and new data on oncogenic drivers offer new therapeutic opportunities.
This review highlights new therapeutic opportunities targeting oncogenic drivers in Ewing's sarcoma to overcome drug resistance.
Outlines potential therapeutic strategies to overcome drug resistance in Ewing's sarcoma; leaves open the.
Ewing's sarcoma (ES) is an aggressive malignant tumor commonly affecting adolescents. The standard of care includes surgical treatment and systemic therapies, although ES patients often develop drug resistance, leading to disease progression. Tumorigenesis in Ewing's sarcoma has unique characteristics that allow for the development of targeted therapeutics. New data on the role of oncogenic drivers in ES tumorigenesis, particularly in relation to treatment-induced stress, offers new therapeutic opportunities. This review summarizes the latest information on the clinically relevant oncogenes found in Ewing's sarcoma, their biological roles, and candidate targets for improving ES patient outcomes.
No takes yet. Share an insight, caveat, or question.
Karlina et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: